ADAMTS-L5 Inhibitors
ADAMTS-L5 inhibitors are not characterized by direct inhibition through binding to the active site or modulating the gene expression of ADAMTS-L5 itself; instead, these inhibitors work by altering the extracellular matrix (ECM) environment in which ADAMTS-L5 operates. The ECM is a complex structure that provides not only mechanical support but also regulates various cellular functions, including those mediated by ADAMTS-L5. Compounds like Marimastat and GM6001 function as broad-spectrum MMP inhibitors and by preserving the ECM, they indirectly affect the activity of ADAMTS-L5. Since ADAMTS-L5 is thought to be involved in the remodeling of the ECM, maintaining ECM integrity through the inhibition of metalloproteases could reduce the functional activity of ADAMTS-L5 by limiting the proteolysis of ECM components.
Similarly, TIMP-2 and TAPI-2, while not directly targeting ADAMTS-L5, play a role in modulating the ECM turnover by inhibiting MMPs, which could lead to reduced ADAMTS-L5 activity due to an alteration in ECM component availability and interaction. Batimastat andIlomastat are synthetic inhibitors designed to bind to the active sites of MMPs, thereby preventing the degradation of ECM components. The inhibition of MMPs by these compounds leads to a less permissive environment for ECM remodeling, which is where ADAMTS-L5 is thought to exert its functional role. By stabilizing the ECM, these inhibitors indirectly limit the capacity of ADAMTS-L5 to interact with and process its substrates. Compounds such as SB-3CT, PD166793, and WAY-170523 offer a more selective approach, targeting specific MMPs like gelatinases and collagenases. This specificity allows for a more targeted modification of the ECM, which can indirectly reduce the activity of ADAMTS-L5 by affecting the ECM components that ADAMTS-L5 might normally modify or by changing the proteolytic dynamics within the ECM.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $165.00 $214.00 $396.00 $617.00 $4804.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloprotease (MMP) inhibitor that can indirectly inhibit ADAMTS-L5 by targeting the proteolytic environment which ADAMTS-L5 is part of, reducing the degradation of extracellular matrix components that ADAMTS-L5 might interact with. | ||||||
TAPI-2 | 187034-31-7 | sc-205851 sc-205851A | 1 mg 5 mg | $280.00 $999.00 | 15 | |
TAPI-2 is an inhibitor of ADAM17 which also has cross-reactivity with other metalloproteases, potentially affecting ADAMTS-L5 activity by altering the proteolytic balance and interactions within the extracellular matrix. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $75.00 $265.00 | 55 | |
GM6001 is a broad-spectrum hydroxamate-based inhibitor of MMPs that can indirectly inhibit ADAMTS-L5 by maintaining extracellular matrix integrity, potentially modifying the substrate availability or interaction profile for ADAMTS-L5. | ||||||
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $175.00 $370.00 | 24 | |
Batimastat is a synthetic inhibitor of MMPs that could reduce the proteolytic activity within the extracellular matrix, thereby indirectly influencing the functional activity of ADAMTS-L5 by altering its interaction with matrix components. | ||||||
SB-3CT | 292605-14-2 | sc-205847 sc-205847A | 1 mg 5 mg | $100.00 $380.00 | 15 | |
SB-3CT is a selective inhibitor of gelatinase A (MMP-2) and gelatinase B (MMP-9), which could impact ADAMTS-L5 function by stabilizing the gelatinous components of the extracellular matrix that ADAMTS-L5 may interact with. | ||||||
PD166793 | 199850-67-4 | sc-202709 | 5 mg | $147.00 | 6 | |
PD166793 is an MMP inhibitor which may indirectly affect ADAMTS-L5 by preserving the extracellular matrix structure, potentially reducing the proteolytic processing in which ADAMTS-L5 could participate. | ||||||
WAY 170523 | 307002-73-9 | sc-361402 sc-361402A | 1 mg 10 mg | $275.00 $595.00 | 1 | |
WAY-170523 is a potent and selective inhibitor of MMP-13, which by reducing MMP-13 activity, could indirectly inhibit ADAMTS-L5 by modifying the extracellular environment and influencing its proteolytic activities. | ||||||
Ro 32-3555 | 190648-49-8 | sc-296277 | 10 mg | $413.00 | 2 | |
Ro 32-3555 is an inhibitor of MMPs, particularly collagenases, and could thereby indirectly influence ADAMTS-L5 activity by limiting collagen degradation and altering the extracellular matrix remodeling that ADAMTS-L5 is involved in. | ||||||
Prinomastat | 192329-42-3 | sc-507449 | 5 mg | $190.00 | ||
Prinomastat is an MMP inhibitor that might indirectly limit the activity of ADAMTS-L5 by preserving the matrix components that ADAMTS-L5 associates with or processes. | ||||||